Property giant Grosvenor has made an investment to support peptides developer Nuritas which has closed $42 million in Series C funding. 

Regarded as a trailblazer in peptide discovery and development, which includes advances in cosmetics/beauty, the funding will enabling Nuritas to scale its operations and expand its global customer base.

Leveraging artificial intelligence (AI) and genomics, Nuritas said it has built the leading discovery and development platform for bioactive, cell signalling peptides – naturally occurring proteins – “empowering consumers to live healthier lives by making the products they consume everyday safer, healthier and more sustainable”.

Nuritas’ portfolio claims 56 clinically-proven patented peptides coving health benefits ranging from strength, energy, and recovery, collagen production, sleep improvement and enhancing metabolism.

Major clients/partners include fragrances/ingredients giant Givaudan. 

Dr Nora Khaldi, founder and CEO of Nuritas, said: “Our mission is to improve the lives of billions by creating ingredients that address pressing global health challenges.

“Through our science-first approach, we are fundamentally shifting the paradigm of ingredient discovery, enabling our customers to deliver healthier, differentiated products that meet the needs of today’s consumers. This investment, alongside the addition of experienced board members, will propel our mission to new heights.”